JPRN-UMIN000021209招募中未知
A phase II trial of tri-week cycle TS-1+L-OHP+Trastuzumab combination therapy for HER2 positive advanced or recurrent gastric cancer - A phase II trial of TS-1+L-OHP+Trastuzumab combination therapy for HER2 positive advanced gastric cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Who cannot administrate TS-1, L-OHP and Trastuzumab 2)Pregnant and / or nursing women or men who wish to have children in future 3)With active infectious disease 4)Positive for HBs antigen 5)Have a history or current symptoms of heart failure, uncontrollable arrhythmia, angina pectoris, valvular disease and uncontrollable hypertension 6)With interstitial pneumonia, pulmonary fibrosis, heart failure, renal failure, hepatic failure and uncontrollable diabetes mellitus 7)With dyspnea at rest 8)With active bleeding from gastric cancer or ulcer 9)With severe diarrhea (over 4 times a day or watery diarrhea) 10)With active double cancers excluding carcinoma in situ and / or prior curative cancer with relapse free for more than 5 years 11)Under medication of flucytosine or phenytoin,or warfarin 13)Under continuous medication of steroids 14)Judged to be unfit for this study by investigator
研究者
相似试验
招募中
2 期
Phase II study of daily administration of TS-1 plus lentinan(LNT) in advanced or recurrent gastric cancer.Advanced or recurrent gastric cancerJPRN-UMIN000008590Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine50
已完成
2 期
A Randomized Phase II/III Trial of Tri-weekly Intravenous versus Tri-weekly Intraperitoneal Carboplatin Both in Combination with Weekly Intravenous Paclitaxel for Newly Diagnosed Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal CancerEpithelial Ovarian, Fallopian Tube, and Primary Peritoneal CancerJPRN-UMIN000003670Gynecologic Oncology Trial and Investigation Consortium / Japanese Gynecologic Oncology Group655
进行中（未招募）
不适用
A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because ofvirologic failure/lack of response. - AVX-303HIV-1MedDRA version: 9.1Level: LLTClassification code 10064446Term: HIV infection WHO clinical stage IEUCTR2008-001486-28-FRAvexa Limited1,866
进行中（未招募）
不适用
A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because ofvirologic failure/lack of response. - 303HIV-1MedDRA version: 9.1Level: LLTClassification code 10064446Term: HIV infection WHO clinical stage IEUCTR2008-001486-28-BEAvexa Limited1,866
进行中（未招募）
不适用
A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because ofvirologic failure/lack of response. - 303HIV-1MedDRA version: 9.1Level: LLTClassification code 10064446Term: HIV infection WHO clinical stage IEUCTR2008-001486-28-DEAvexa Limited1,866